Company Profile
|
Barinthus Biotherapeutics plc
(NASDAQ: BRNS)
|
5:00 PM UTC, 07/03/24 | |||
|---|---|---|---|---|
| Last: $1.43 | Change: -0.00 | %Change: -0.25% | Volume: 6,054 | |
Detailed Quote
M = Million B = Billion
Price Performance
Management Effectiveness
Profitability
| Open: | $ 1.43 | Volume: | 6,054 | |
|---|---|---|---|---|
| High: | $ 1.43 | Yield(%) | 0.00 | |
| Low: | $ 1.33 | P/E Ratio (ttm): | n/a | |
| Dividend ($): | n/a | Market Cap ($): | 55.70M | |
| EPS ($) | -1.84 | Shares Out: | 38.95M |
| % Price Change (last 4 weeks): | -24.15 |
|---|---|
| % Price Change (last 13 weeks): | -39.51 |
| % Price Change (last 26 weeks): | -61.25 |
| % Price Change (last 52 weeks): | -37.12 |
| % Price Change (year to date): | -61.25 |
| Return on Equity (%): | -34.27 |
|---|---|
| Return on Assets (%): | -29.17 |
| Return on Invested Capital (%): | -32.17 |
| Gross Profit Margin (%): | -576.93 |
|---|---|
| Net Profit Margin (%): | -9145.51 |
| Operating Profit Margin (%): | -11417.58 |
Price & Volume
Company Information
Per Share Data
Valuation Ratios
Financial Strength
|
|
|
| 50-day Moving Average: | $2.02 |
|---|---|
| 200-day Moving Average: | $n/a |
| Avg. Daily Vol. (last 50 days): | 23,133 |
| Avg. Daily Vol. (last 200 days): | n/a |
| 52-wk high: | $n/a |
| 52-wk low: | $n/a |
| Bid: | $1.40 |
| Ask: | $1.43 |
|
Barinthus Biotherapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. It also focuses on the pipeline of both clinical and preclinical stage therapeutic, and prophylactic programs. The company was founded by Adrian Hill and Dame Sarah Gilbert in March 2021 and is headquartered in Didcot, the United Kingdom.
|
|
Barinthus Biotherapeutics plc
Zeus Building Rutherford Avenue Unit 6-10, Harwell Didcot OX OX11 0DF Phone: 44.18.6581.8808 Fax: n/a http://www.vaccitech.co.uk |
| Earnings (1year) ($): | n/a |
|---|---|
| Annual Dividend ($): | 0.00 |
| Current P/E Ratio (ttm): | n/a |
| Book Value ($): | 4.83 |
| Cash Flow ($): | -1.76 |
| Price/Earnings (x): | n/a |
|---|---|
| Price/Sales (x): | 175.93 |
| Price/Book (x): | 0.76 |
| Price/Cash Flow (x): | n/a |
| Quick Ratio (x): | 12.45 |
|---|---|
| Current Ratio (x): | 12.45 |
| LT Debt/Equity (x): | 5.99 |
| Total Debt/Equity (x): | 6.95 |
